CA
NZ
UK
AU
IND
US
Tradewinds Universal (OTC:TRWD) is about as far from a conventional health-or-technology story as aStock Screeneris likely to surface: a sub-penny, over-the-counter name in the middle of a dramatic reinvention. Shares closed up 8.33% at $0.01 at last closing, but at a fraction of a …
Few micro-cap biotechs have assembled aLeadershiproster quite like Turn Therapeutics Inc (NASDAQ:TTRX). The clinical-stage skin-disease specialist has drawn attention less for a single product milestone than for the marquee names now attached to its research effort, and its shares closed down 5.16% at $12.69 …
Barely a month after pricing its market debut, Vogenx, Inc. (NASDAQ: VOGX) surged in the September 2026 session, closing up 9.54% at $32.71 at last closing. The metabolic-disease developer has been one of a wave of new biotech listings this year, and its early …
Commercial-stageMedTechnames rarely blend a fresh IPO, real revenue and clinical validation, but Mobia Medical is doing exactly that. Shares closed down 2.34% at $10.01 at last closing, a modest dip for a company that came public in May 2026 and has since posted brisk …
MapLight Therapeutics, Inc. (NASDAQ:MPLT) has been one of the more closely tracked neuroscience names to reach public markets in the past year, and its shares closed down 5.69% at $13.00 at last closing. After debuting in late 2025, the stock has swung across a …
A gain in Odyssey Therapeutics, Inc (NASDAQ:ODTX) has put the clinical-stage biopharmaceutical company back in the spotlight only months after its market debut. Shares closed up 4.19% at $24.63 at last closing, a move large enough to draw notice but not obviously tied to …
Parabilis Medicines, Inc. (NASDAQ:PBLS) has been one of the more talked-about biotech debutants of 2026, and its shares ticked up 1.54% to $36.88 at last closing after a strong post-IPO run. The company is attempting something the industry has long chased: drugging targets that …
Regentis Biomaterials Ltd (NYSE American:RGNT) occupies a very different corner of healthcare from the billion-dollar biotechs dominating headlines. Shares closed down 3.57% at $1.89 at last closing, a small move for a thinly traded stock, and one without any confirmed news behind it. The …
Atrium Therapeutics, Inc. is a fresh face onNasdaqwearing a familiar badge: the company inherited the well-known RNA ticker when it became an independent, publicly tradedBusinessearlier in 2026. Shares closed essentially flat at last closing, up 0.10% at $10.36, fitting the pattern of a small, …
A newly public CRISPR company edged higher in September 2026, and the move offered a reminder that fresh biotech listings rarely trade in a straight line. Scribe Therapeutics Inc (NASDAQ:SCTX), which debuted on the Nasdaq only weeks earlier, closed up 0.92% at $29.74 at …
Please wait processing your request...